# Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R

> **NCT00534469** · PHASE2 · COMPLETED · sponsor: **City of Hope Medical Center** · enrollment: 60 (actual)

## Conditions studied

- Leukemia

## Interventions

- **BIOLOGICAL:** aldesleukin
- **BIOLOGICAL:** filgrastim
- **DRUG:** busulfan
- **DRUG:** cytarabine
- **DRUG:** etoposide
- **DRUG:** idarubicin
- **PROCEDURE:** autologous hematopoietic stem cell transplantation
- **PROCEDURE:** bone marrow transplantation
- **PROCEDURE:** peripheral blood stem cell transplantation
- **RADIATION:** total-body irradiation

## Key facts

- **NCT ID:** NCT00534469
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-02-08
- **Primary completion:** 2022-12-31
- **Final completion:** 2025-07-16
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-12-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00534469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00534469, "Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT00534469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*